Compound-13-(GSK716)

mutant alpha-1-antitrypsin folding corrector

sub-µM in cell, high predicted human %F

from 2T component DEL + SBDD

Bioorg. Med. Chem. Lett., Mar. 19, 2021

GlaxoSmithKline, Stevenage, UK / UCL

The GlaxoSmithKline (GSK) Z α1-antitrypsin stabilizer (“compound 13,” GSK716) acts by blocking the formation of polymers within the endoplasmic reticulum of hepatocytes for treatment of α1-antitrypsin deficiency. It was…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.